MarginsXMarginsX
Home › Markets › Health Care › ENTX

Entera Bio Ltd. (ENTX)

ENTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.02
-2.89% on the day
Market cap
$525.9M
Small cap
Revenue · 2025
$42K
-76.8% on 2024
Net income · 2025
-$11.4M
-27235.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1638097/000117891326001797/0001178913-26-001797-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerENTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryIsrael
IPO year2018
SEC CIK0001638097
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inIsrael

Financials · 2025

LineValue
Revenue$42K
Net income-$11.4M
Operating income-$11.5M
Net margin-27235.7%
Operating margin-27450.0%
Revenue growth-76.8%
Cash$7.1M
Total assets$16.0M
P/E (computed)Net income was not positive
P/S (computed)12521.3×

Warning signs

Cash runway
202.1 months
$265.9M cash at September 30, 2026
Share count, 1 year
+279.7%
2025-11-10 to 2026-11-02 · +504.4% over 3 years
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
$141K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-06
Cash and burn$265.9M cash; operating cash flow -$3.9M a quarter.Report 2026-09-30
Shares outstanding174,137,771 (2026-11-02); 45,857,242 a year earlier; 28,813,952 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-08-21
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKesselman & Kesselman C.P.A.s, Tel-Aviv, IsraelPCAOB Form AP 2026-04-12
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $141K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$15.6M-$7.4M$265.9M$378K$010-Q 2026-11-06
Q2 2026
2026-06-30
$0-$7.3M-$3.5M$11.3M$284K$010-Q 2026-08-07
Q1 2026
2026-03-31
$0-$3.5M-$3.1M$4.1M$567K$010-Q 2026-05-08
Q4 2025
2025-12-31
$0-$3.0M-$1.8M$7.1M$393K$42K10-K 2026-03-27
Q3 2025
2025-09-30
$0-$3.2M-$2.5M$8.6M$527K$124K10-Q 2026-11-06
Q2 2025
2025-06-30
$0-$2.7M-$1.6M$10.9M$524K$166K10-Q 2026-08-07
Q1 2025
2025-03-31
$42K-$2.6M-$1.4M$12.6M$515K$223K10-Q 2026-05-08
Q4 2024
2024-12-31
$82K-$2.4M-$1.5M$8.7M$0$181K10-K 2026-03-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-08-28
Latest annual report10-K2026-03-27
Latest quarterly / interim10-Q2026-11-06
Latest current report8-K2026-11-06
Latest proxyDEF 14A2026-10-14

Source: SEC EDGAR submissions feed, 421 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.0%
1 month+24.9%
3 months+8.4%
Year to date+60.3%
1 year+13.5%
From 52-week high-20.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ETRAElectra Therapeutics Inc.$8.31-6.00%$522.4M
VALNValneva SE$5.65-0.18%$536.1M
DNAGinkgo Bioworks Holdings Inc.$8.50-11.55%$551.0M
IAMIambic Therapeutics Inc.$11.85-9.54%$561.7M
SANASana Biotechnology Inc.$1.88-6.93%$563.3M
RGNXREGENXBIO Inc.$7.32-4.19%$484.0M
CADLCandel Therapeutics Inc.$5.81-6.29%$455.8M
FENCFennec Pharmaceuticals Inc.$12.76+9.81%$450.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier